1. Home
  2. Products
  3. Customized ADCs
  4. ER-a36
  5. Anti-ER-a36-Mc-MMAF ADC

Anti-ER-a36-Mc-MMAF ADC (CAT#: ADC-W-204)

This ADC product is comprised of an anti-ER-a36 monoclonal antibody (clone SNGmB) conjugated via a Mc linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • Product Information
  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Antibody clone #
  • SNGmBI
  • Name
  • ER-a36
  • Alternative Names
  • ER; ESR; Era; ESRA; ESTRR; NR3A1
  • Target Entrez Gene ID
  • 2099
  • Overview
  • This gene is a 36 kDa variant of hER-a, it lacks the N-terminal AF-1 domain and the C-terminal AF-2 domain of hER-a. hER-a is one of the two types of estrogen receptors discovered in human cells (hERs). hERs encodes an estrogen receptor, a ligand-activated transcription factor composed of several domains important for hormone binding, DNA binding, and activation of transcription.
  • Overview
  • Anti-ER-a36 mlgG2b antibody, clone # SNGmBI
  • Clone #
  • SNGmBI
  • Host animal
  • Mouse
  • Species Reactivity
  • Human
  • Name
  • Mc (maleimidocaproyl)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • MMAF (Monomethyl auristatin F)
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-204. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-206 Anti-ER-a36-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-205 Anti-ER-a36-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-207 Anti-ER-a36-MB-VC-duocarmycin ADC MB-VC duocarmycin
ADC-W-203 Anti-ER-a36-Mc-VC-PABC-MMAE ADC MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE (Monomethyl auristatin E)
CAT# Product Name Linker Payload
ADC-W-517 Anti-TM4SF1-Mc-LP2 ADC-1 Mc (maleimidocaproyl) LP2 (chemical name mc-3377)
ADC-W-537 Anti-TPBG-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-114 Anti-CD33-Mc-MMAF ADC-3 Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-478 Anti-ENPP3-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-322 Anti-CD19-Mc-MMAF ADC-1 Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
CAT# Product Name Linker Payload
ADC-AA-053 Protein A-MMAF ADC MMAF (Monomethyl auristatin F)
ADC-AA-027 anti-MIgG(Fc)Fab-N-MMAF ADC Noncleavable linkers MMAF (Monomethyl auristatin F)
ADC-AA-019 anti-MIgG(Fc)-N-MMAF ADC Noncleavable linkers MMAF (Monomethyl auristatin F)
ADC-AA-001 anti-HIgG(Fc)-N-MMAF ADC Noncleavable linkers MMAF (Monomethyl auristatin F)
ADC-AA-002 anti-HIgG(Fc)-C-MMAF ADC Cleavable linkers MMAF (Monomethyl auristatin F)

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.